Amprion, Inc.
San Francisco, CA
- UEI
- QBCELFPYPNJ3
- CAGE
- 6EHJ4
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 149 New Montgomery St Fl 4, San Francisco, CA 94105, USA
- Website
- ampriondx.com
- Founded
- 2007
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $598,400 |
| FY2024 | $528,000 |
| FY2023 | $1,064,800 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Protein analysis in cerebrospinal fluid samples | National Institute on Drug Abuse (NIH) | $1,126,400 | |
| Protein analysis in cerebrospinal fluid samples | National Institute on Drug Abuse (NIH) | $1,064,800 |
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| CND Life Sciences, Inc. | Scottsdale, AZ | 621511 Medical Laboratories |
| Neurodex Inc. | Natick, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer | Barcelona, CT | 813212 Voluntary Health Organizations |
| Aivocode, Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Dzne E.V. | Bonn, NRW | — |
About the company
Amprion, Inc. is a for-profit corporate entity registered in SAM.gov since May 27, 2011, specializing in advanced neurological diagnostic services with a focus on protein analysis, particularly in the domain of neurodegenerative diseases. The company provides sophisticated protein analysis services centered on detecting alpha-synuclein aggregates in cerebrospinal fluid samples, utilizing its proprietary SYNTap assay technology. The organization has demonstrated significant expertise in neurological research, specifically targeting diagnostic methodologies for understanding complex neurological conditions like Alzheimer's Disease, Parkinson's Disease, and Related Dementias.
Through its federal contract awards, Amprion, Inc. has consistently worked with the National Institute on Aging (NIA), a civilian agency within the U.S. Department of Health and Human Services, to perform specialized protein analysis services. The company has secured multiple purchase order contracts, including a significant $2,640,000 contract awarded on August 1, 2024, for analyzing 1,200 cerebrospinal fluid samples with potential expansion to 4,800 samples. These contracts are not set-aside and were originally posted under small business sources sought notices, indicating Amprion's competitive capabilities in neurological diagnostic research. The contracts specifically involve detailed protein analysis in cerebrospinal fluid samples, demonstrating the company's technical expertise in handling complex medical research materials.
In the federal grant space, Amprion, Inc. has received awards from the National Institute of Neurological Disorders and Stroke, most notably a cooperative agreement grant (U44NS111672) awarded on May 15, 2020. This grant, valued at $1,064,800, focused on the analytical validation of a biochemical test for alpha-synuclein aggregates in biological fluids, specifically for diagnosing Parkinson's Disease. The grant supported research aimed at developing and validating advanced diagnostic techniques, with a performance period from May 15, 2020, to April 30, 2021. This grant award further underscores Amprion's commitment to innovative neurological research and diagnostic methodology development.
Quick answers
Is Amprion, Inc. registered in SAM.gov?
Yes. Amprion, Inc.'s SAM.gov registration is active through November 17, 2026.
What is Amprion, Inc.'s CAGE code?
Amprion, Inc.'s CAGE code is 6EHJ4, and its Unique Entity ID (UEI) is QBCELFPYPNJ3.
How much has Amprion, Inc. received in federal contracts?
Federal contracts obligated $598,400 to Amprion, Inc. in fiscal year 2025 and $2,191,200 in fiscal years 2023 through 2027.
How does Amprion, Inc. rank among federal contractors?
Amprion, Inc. ranked #61 in NAICS 621511, #82 in NAICS 6215 and #85 in PSC Q3 in FY2025.
What is Amprion, Inc.'s most recent federal award?
Amprion, Inc.'s most recent federal contract award is Protein analysis in cerebrospinal fluid samples (75N95024P00382), from National Institute on Drug Abuse (NIH), on August 1, 2024.
On GovTribe
See Amprion, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors